Larissa J Mooney

Title(s)Professor of Clinical , Psychiatry and Biobehavioral Sciences
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Greater Southern California Node of the Clinical Trials Network
    NIH UG1DA049435Jun 1, 2019 - Feb 29, 2024
    Role: Co-Principal Investigator
    Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function
    NIH R01DA045162Jul 1, 2018 - Apr 30, 2023
    Role: Co-Principal Investigator
    Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder
    NIH R33DA045844Sep 1, 2017 - Aug 31, 2021
    Role: Co-Principal Investigator
    Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder
    NIH R21DA045844Sep 1, 2017 - Aug 31, 2018
    Role: Co-Principal Investigator
    Assessing Functional Outcomes Associated with Reductions in Cannabis Use
    NIH R33DA042280Aug 1, 2016 - Jan 31, 2022
    Role: Co-Principal Investigator
    Assessing Functional Outcomes Associated with Reductions in Cannabis Use
    NIH R21DA042280Aug 1, 2016 - Dec 31, 2018
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder. Ann Med. 2023 Dec; 55(1):480-489. Clingan SE, Cousins SJ, Lin C, Nguyen TE, Hser YI, Mooney LJ. PMID: 36692029.
      View in: PubMed   Mentions:    Fields:    
    2. Care coordination between rural primary care and telemedicine to expand medication treatment for opioid use disorder: Results from a single-arm, multisite feasibility study. J Rural Health. 2023 Apr 19. Hser YI, Mooney LJ, Baldwin LM, Ober A, Marsch LA, Sherman S, Matthews A, Clingan S, Fei Z, Zhu Y, Dopp A, Curtis ME, Osterhage KP, Hichborn EG, Lin C, Black M, Calhoun S, Holtzer CC, Nesin N, Bouchard D, Ledgerwood M, Gehring MA, Liu Y, Ha NA, Murphy SM, Hanano M, Saxon AJ. PMID: 37074350.
      View in: PubMed   Mentions:    Fields:    
    3. Alcohol Use Among Treatment-Seeking Individuals with Opioid Use Disorder. J Stud Alcohol Drugs. 2023 Apr 19. Baskerville WA, Grodin EN, Lin J, Miotto K, Mooney LJ, Ray LA. PMID: 37096768.
      View in: PubMed   Mentions:    Fields:    
    4. Psychosis among individuals with methamphetamine use disorder is associated with elevated rates of hospitalizations and emergency department visits across an academic health care system. J Subst Use Addict Treat. 2023 Apr 01; 209033. Zito MF, Fei Z, Zhu Y, Clingan SE, Marder SR, Mooney LJ. PMID: 37011880.
      View in: PubMed   Mentions:
    5. Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. Drug Alcohol Depend. 2023 01 01; 242:109711. Lin C, Pham H, Zhu Y, Clingan SE, Lin LA, Murphy SM, Campbell CI, Sorrell TR, Liu Y, Mooney LJ, Hser YI. PMID: 36462230; PMCID: PMC9683518.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    6. Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state. Subst Abuse Treat Prev Policy. 2022 05 08; 17(1):36. Padwa H, Huang D, Mooney L, Grella CE, Urada D, Bell DS, Bass B, Boustead AE. PMID: 35527269; PMCID: PMC9080201.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    7. The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study. Addiction. 2022 09; 117(9):2438-2447. Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser YI, McHugh RK, McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE, Weiss RD, Wu LT. PMID: 35293064; PMCID: PMC9543602.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Medication Treatment for Opioid Use Disorder Reduces Suicide Risk. Am J Psychiatry. 2022 04; 179(4):262-263. Mooney LJ. PMID: 35360917.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2022 05; 175(5):720-731. Perry C, Liberto J, Milliken C, Burden J, Hagedorn H, Atkinson T, McKay JR, Mooney L, Sall J, Sasson C, Saxon A, Spevak C, Gordon AJ, VA/DoD Guideline Development Group. PMID: 35313113.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    10. Association Between Benzodiazepine and Opioid Prescription and Mortality Among Patients in a Large Healthcare System. J Addict Med. 2022 Jan-Feb 01; 16(1):65-71. Mooney LJ, Zhu Y, Yoo CK, Wolitzky-Taylor K, Hser YI. PMID: 35120065; PMCID: PMC8817063.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Social Determinants of Mortality of COVID-19 and Opioid Overdose in American Rural and Urban Counties. J Addict Med. 2022 Jan-Feb 01; 16(1):e52-e55. Zhu Y, Fei Z, Mooney LJ, Huang K, Hser YI. PMID: 35120068; PMCID: PMC8815643.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    12. Craving among individuals with stimulant use disorder in residential social model-based treatment - Can exercise help? Drug Alcohol Depend. 2022 02 01; 231:109247. Salem BA, Gonzales-Castaneda R, Ang A, Rawson RA, Dickerson D, Chudzynski J, Penate J, Dolezal B, Cooper CB, Mooney LJ. PMID: 34999268.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021 11 01; 228:108996. Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser YI. PMID: 34555691; PMCID: PMC8674982.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    14. Disparities in digital access among American rural and urban households and implications for telemedicine-based services. J Rural Health. 2022 06; 38(3):512-518. Curtis ME, Clingan SE, Guo H, Zhu Y, Mooney LJ, Hser YI. PMID: 34355427.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    15. Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine. Adv Drug Alcohol Res. 2021; 1. Cameron CM, Nieto S, Bosler L, Wong M, Bishop I, Mooney L, Cahill CM. PMID: 35265942; PMCID: PMC8903193.
      View in: PubMed   Mentions:
    16. The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives. J Subst Abuse Treat. 2022 02; 133:108544. Lin C, Clingan SE, Cousins SJ, Valdez J, Mooney LJ, Hser YI. PMID: 34183213; PMCID: PMC8702565.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsPHPublic Health
    17. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022 01; 117(1):151-161. Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. PMID: 34105213; PMCID: PMC8710136.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. Addict Sci Clin Pract. 2021 04 20; 16(1):24. Hser YI, Ober AJ, Dopp AR, Lin C, Osterhage KP, Clingan SE, Mooney LJ, Curtis ME, Marsch LA, McLeman B, Hichborn E, Lester LS, Baldwin LM, Liu Y, Jacobs P, Saxon AJ. PMID: 33879260; PMCID: PMC8056373.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    19. Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study. Trials. 2021 Jan 28; 22(1):102. Karnik NS, Campbell CI, Curtis ME, Fiellin DA, Ghitza U, Hefner K, Hser YI, McHugh RK, Murphy SM, McPherson SM, Moran L, Mooney LJ, Wu LT, Shmueli-Blumberg D, Shulman M, Schwartz RP, Stephens KA, Watkins KE, Marsden J. PMID: 33509278; PMCID: PMC7841754.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    20. Effect of screening, brief intervention and referral to treatment for unhealthy alcohol and other drug use in mental health treatment settings: a randomized controlled trial. Addiction. 2021 01; 116(1):159-169. Karno MP, Rawson R, Rogers B, Spear S, Grella C, Mooney LJ, Saitz R, Kagan B, Glasner S. PMID: 32415721; PMCID: PMC7666646.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    21. Integrating Telemedicine for Medication Treatment for Opioid Use Disorder in Rural Primary Care: Beyond the COVID Pandemic. J Rural Health. 2021 01; 37(1):246-248. Hser YI, Mooney LJ. PMID: 32579751; PMCID: PMC7361555.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    22. The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2020 03; 112S:4-11. Marsch LA, Campbell A, Campbell C, Chen CH, Ertin E, Ghitza U, Lambert-Harris C, Hassanpour S, Holtyn AF, Hser YI, Jacobs P, Klausner JD, Lemley S, Kotz D, Meier A, McLeman B, McNeely J, Mishra V, Mooney L, Nunes E, Stafylis C, Stanger C, Saunders E, Subramaniam G, Young S. PMID: 32220409; PMCID: PMC7134325.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    23. Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results. J Subst Abuse Treat. 2020 01; 108:115-122. Mooney LJ, Valdez J, Cousins SJ, Yoo C, Zhu Y, Hser YI. PMID: 31668516; PMCID: PMC7397558.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. Medication Adherence Monitoring Using Smartphone Video Dosing in an Open-label Pilot Study of Monthly Naltrexone Plus Once-daily Bupropion for Methamphetamine Use Disorder: Feasibility and Acceptability. J Addict Med. 2019 Sep/Oct; 13(5):372-378. Walker R, Hillhouse M, Perrochet B, Sparenborg S, Mooney L, Ling W. PMID: 30724759; PMCID: PMC6675664.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks, Offering a Public Health Perspective-A Commentary on Camenga et al. J Stud Alcohol Drugs. 2019 07; 80(4):403-405. Gonzales-Castaneda R, Mooney LJ, Rawson RA. PMID: 31495375; PMCID: PMC6739646.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    26. Relationships between marijuana use, severity of marijuana-related problems, and health-related quality of life. Psychiatry Res. 2019 09; 279:237-243. Liao JY, Mooney LJ, Zhu Y, Valdez J, Yoo C, Hser YI. PMID: 30876731; PMCID: PMC6713587.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    27. Escalating Opioid Dose Is Associated With Mortality: A Comparison of Patients With and Without Opioid Use Disorder. J Addict Med. 2019 Jan/Feb; 13(1):41-46. Hser YI, Saxon AJ, Mooney LJ, Miotto K, Zhu Y, Yoo CK, Liang D, Huang D, Bell DS. PMID: 30418260; PMCID: PMC6349485.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    28. Reduction in Cannabis Use and Functional Status in Physical Health, Mental Health, and Cognition. J Neuroimmune Pharmacol. 2018 12; 13(4):479-487. Mooney LJ, Zhu Y, Yoo C, Valdez J, Moino K, Liao JY, Hser YI. PMID: 30284156; PMCID: PMC6293461.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    29. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol. 2018 12; 13(4):488-497. Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI. PMID: 30094695; PMCID: PMC6224303.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    30. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017 10; 81:53-58. Hser YI, Mooney LJ, Huang D, Zhu Y, Tomko RL, McClure E, Chou CP, Gray KM. PMID: 28847455; PMCID: PMC5607644.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    31. High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System. J Addict Med. 2017 Jul/Aug; 11(4):315-319. Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Zhu Y, Liang D, Huang D. PMID: 28426439; PMCID: PMC5930020.
      View in: PubMed   Mentions: 50     Fields:    
    32. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257. Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR. PMID: 28623823; PMCID: PMC5535813.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimals
    33. Chronic pain among patients with opioid use disorder: Results from electronic health records data. J Subst Abuse Treat. 2017 06; 77:26-30. Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. PMID: 28476267; PMCID: PMC5424616.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    34. Mindfulness Based Relapse Prevention for Stimulant Dependent Adults: A Pilot Randomized Clinical Trial. Mindfulness (N Y). 2017 Feb; 8(1):126-135. Glasner-Edwards S, Mooney LJ, Ang A, Garneau HC, Hartwell E, Brecht ML, Rawson RA. PMID: 28191264; PMCID: PMC5300086.
      View in: PubMed   Mentions: 25  
    35. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. J Addict Med. 2016 Jul-Aug; 10(4):236-43. Mooney LJ, Hillhouse MP, Thomas C, Ang A, Sharma G, Terry G, Chang L, Walker R, Trivedi M, Croteau D, Sparenborg S, Ling W. PMID: 27379819; PMCID: PMC4969133.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016 08; 111(8):1416-27. Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J. PMID: 26948856; PMCID: PMC4940267.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    37. Effect of Exercise Training on Striatal Dopamine D2/D3 Receptors in Methamphetamine Users during Behavioral Treatment. Neuropsychopharmacology. 2016 May; 41(6):1629-36. Robertson CL, Ishibashi K, Chudzynski J, Mooney LJ, Rawson RA, Dolezal BA, Cooper CB, Brown AK, Mandelkern MA, London ED. PMID: 26503310; PMCID: PMC4832026.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    38. Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. Am J Addict. 2015 Oct; 24(7):667-75. Jacobs P, Ang A, Hillhouse MP, Saxon AJ, Nielsen S, Wakim PG, Mai BE, Mooney LJ, S Potter J, Blaine JD. PMID: 26400835; PMCID: PMC5322942.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    39. Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care. Drug Alcohol Depend. 2015 Nov 01; 156:21-28. Rawson RA, Chudzynski J, Mooney L, Gonzales R, Ang A, Dickerson D, Penate J, Salem BA, Dolezal B, Cooper CB. PMID: 26371404; PMCID: PMC4633370.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansPHPublic Health
    40. The Impact of Exercise On Depression and Anxiety Symptoms Among Abstinent Methamphetamine-Dependent Individuals in A Residential Treatment Setting. J Subst Abuse Treat. 2015 Oct; 57:36-40. Rawson RA, Chudzynski J, Gonzales R, Mooney L, Dickerson D, Ang A, Dolezal B, Cooper CB. PMID: 25934458; PMCID: PMC4560957.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    41. Predictors of depression outcomes among abstinent methamphetamine-dependent individuals exposed to an exercise intervention. Am J Addict. 2015 Apr; 24(3):246-251. Haglund M, Ang A, Mooney L, Gonzales R, Chudzynski J, Cooper CB, Dolezal BA, Gitlin M, Rawson RA. PMID: 25907813.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    42. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014 Dec; 28(12):1115-26. Glasner-Edwards S, Mooney LJ. PMID: 25373627; PMCID: PMC5027896.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    43. Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials. 2014 Nov; 39(2):211-23. McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, Gray KM. PMID: 25179587; PMCID: PMC4252394.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    44. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014 Sep; 109(9):1489-500. Ling W, Chang L, Hillhouse M, Ang A, Striebel J, Jenkins J, Hernandez J, Olaer M, Mooney L, Reed S, Fukaya E, Kogachi S, Alicata D, Holmes N, Esagoff A. PMID: 24825486; PMCID: PMC4127124.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    45. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users. J Subst Abuse Treat. 2015 Jan; 48(1):70-6. Nielsen S, Hillhouse M, Mooney L, Ang A, Ling W. PMID: 25065489; PMCID: PMC4250309.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    46. Exercise training improves heart rate variability after methamphetamine dependency. Med Sci Sports Exerc. 2014 Jun; 46(6):1057-66. Dolezal BA, Chudzynski J, Dickerson D, Mooney L, Rawson RA, Garfinkel A, Cooper CB. PMID: 24162556; PMCID: PMC3999306.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    47. Exercise for methamphetamine dependence: rationale, design, and methodology. Contemp Clin Trials. 2014 Jan; 37(1):139-47. Mooney LJ, Cooper C, London ED, Chudzynski J, Dolezal B, Dickerson D, Brecht ML, Peñate J, Rawson RA. PMID: 24291456; PMCID: PMC4431553.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    48. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. Am J Addict. 2014 Jul-Aug; 23(4):343-8. Nielsen S, Hillhouse M, Weiss RD, Mooney L, Sharpe Potter J, Lee J, Gourevitch MN, Ling W. PMID: 24112096; PMCID: PMC4151625.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    49. Does Posttraumatic Stress Disorder (PTSD) Affect Post-Treatment Methamphetamine Use? J Dual Diagn. 2013 Apr 01; 9(2):123-128. Glasner-Edwards S, Mooney LJ, Ang A, Hillhouse M, Rawson R. PMID: 24065875; PMCID: PMC3779468.
      View in: PubMed   Mentions: 6     Fields:    
    50. Eight weeks of exercise training improves fitness measures in methamphetamine-dependent individuals in residential treatment. J Addict Med. 2013 Mar-Apr; 7(2):122-8. Dolezal BA, Chudzynski J, Storer TW, Abrazado M, Penate J, Mooney L, Dickerson D, Rawson RA, Cooper CB. PMID: 23552821; PMCID: PMC3617407.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    51. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. Contemp Clin Trials. 2013 Mar; 34(2):196-204. Mooney LJ, Nielsen S, Saxon A, Hillhouse M, Thomas C, Hasson A, Stablein D, McCormack J, Lindblad R, Ling W. PMID: 23159524; PMCID: PMC3760415.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Advances in opioid antagonist treatment for opioid addiction. Psychiatr Clin North Am. 2012 Jun; 35(2):297-308. Ling W, Mooney L, Wu LT. PMID: 22640757; PMCID: PMC4178977.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    53. Comparing buprenorphine induction experience with heroin and prescription opioid users. J Subst Abuse Treat. 2012 Oct; 43(3):285-90. Nielsen S, Hillhouse M, Mooney L, Fahey J, Ling W. PMID: 22301084; PMCID: PMC3350757.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    54. Selective review and commentary on emerging pharmacotherapies for opioid addiction. Subst Abuse Rehabil. 2011; 2:181-8. Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K. PMID: 24474855; PMCID: PMC3846315.
      View in: PubMed   Mentions: 4  
    55. Bulimia nervosa among methamphetamine dependent adults: association with outcomes three years after treatment. Eat Disord. 2011 May-Jun; 19(3):259-69. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. PMID: 21516550; PMCID: PMC3159413.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    56. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev. 2011 May; 30(3):300-5. Ling W, Mooney L, Hillhouse M. PMID: 21545561; PMCID: PMC4170948.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    57. Prescription and over-the-counter drug treatment admissions to the California public treatment system. J Subst Abuse Treat. 2011 Apr; 40(3):224-9. Gonzales R, Brecht ML, Mooney L, Rawson RA. PMID: 21193282; PMCID: PMC4018412.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    58. Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning. Am J Addict. 2010 Sep-Oct; 19(5):385-90. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine Treatment Project Corporate Authors. PMID: 20716300; PMCID: PMC3159418.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    59. The relationship between methamphetamine use and increased dental disease. J Am Dent Assoc. 2010 Mar; 141(3):307-18. Shetty V, Mooney LJ, Zigler CM, Belin TR, Murphy D, Rawson R. PMID: 20194387; PMCID: PMC2947197.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    60. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev. 2010 Jan; 29(1):12-20. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA, Methamphetamine Treatment Project Corporate Authors. PMID: 20078677; PMCID: PMC3772133.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    61. The methamphetamine problem in the United States. Annu Rev Public Health. 2010; 31:385-98. Gonzales R, Mooney L, Rawson RA. PMID: 20070191; PMCID: PMC4440680.
      View in: PubMed   Mentions: 125     Fields:    Translation:Humans
    62. Health conditions in methamphetamine-dependent adults 3 years after treatment. J Addict Med. 2009 Sep; 3(3):155-63. Mooney LJ, Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Hunter J, Haning W, Colescott P, Ling W, Rawson R. PMID: 21769012.
      View in: PubMed   Mentions: 7     Fields:    
    63. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009 Apr; 197(4):225-31. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R, Methamphetamine Treatment Project Corporate Authors. PMID: 19363377; PMCID: PMC2749575.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    64. Hepatitis A and B infection among methamphetamine-dependent users. J Subst Abuse Treat. 2008 Oct; 35(3):351-2. Gonzales R, Marinelli-Casey P, Hillhouse M, Hunter J, Rawson RA, Mooney L, Ang A. PMID: 18640808.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    65. Identifying methamphetamine users at risk for major depressive disorder: findings from the methamphetamine treatment project at three-year follow-up. Am J Addict. 2008 Mar-Apr; 17(2):99-102. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine Treatment Project. PMID: 18393051.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    66. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. 2008 Dec; 35(4):445-50. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine Treatment Project Corporate Authors. PMID: 18294802.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    67. Risk factors for suicide attempts in methamphetamine-dependent patients. Am J Addict. 2008 Jan-Feb; 17(1):24-7. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine Treatment Project. PMID: 18214719.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    68. Predatory behavior of Polistes dominulus wasps in response to cardenolides and glucosinolates in Pieris napi caterpillars. J Chem Ecol. 2007 Jun; 33(6):1177-85. Rayor LS, Mooney LJ, Renwick JA. PMID: 17453324.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    Larissa's Networks
    Concepts (212)
    Derived automatically from this person's publications.
    Co-Authors (14)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department